David Fineman co-founded KineMed, Inc. and has served as a member of the board of directors and Chairman and Chief Executive Officer since February 2001, and as President from February 2001 to July 2013. Previously, Mr. Fineman co-founded SuperGen, Inc. in 1990, a public pharmaceutical company, now Astex Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceuticals Co. Ltd. in October 2013, where he had served as Chief Financial Officer and served on the board of directors. Mr. Fineman also co-founded Quark Pharmaceuticals, Inc. in 1992. Mr. Fineman received a B.A. in English from the University of Maryland and an M.A. in Psychology from the Graduate Faculty of the New School for Social Research.
Chairman & Chief Executive Officer
KineMed is led by a talented team of seasoned leaders with a unique combination of expertise in medicine, pharmacology, drug discovery and development, and the creation and financing of successful biomedical enterprises.
Our combination of scientific and business expertise allows KineMed to pursue academic and industry-based collaborations as well as its internal drug development programs for expedited value creation.
Members of the KineMed management team bring a wealth of hands-on experience in drug development to KineMed as well as a validated approach to the application of translational and personalized medicine.